NGM - NGM Biopharmaceuticals, Inc.
After hours:
Chart Events
Short-term KST
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 3.6200 |
| Open | 3.6500 |
| Bid | 0.0000 x 1000 |
| Ask | 0.0000 x 900 |
| Day's Range | 3.5815 - 3.7500 |
| 52 Week Range | 2.8400 - 18.2500 |
| Volume | |
| Avg. Volume | 307,226 |
| Market Cap | 307.199M |
| Beta (5Y Monthly) | 1.20 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.5600 |
| Earnings Date | Aug 02, 2023 - Aug 07, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.00 |
Fair Value
Related Research
GlobeNewswireNGM Bio to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an overview of the company and provide a business update at the following upcoming investor conferences. Cowen 4th Annual Oncology Innovation SummitWednesday, May 31, 2023, 2:00 pm ET Jefferies
- GlobeNewswire
NGM Bio Announces Presentation of Data from Phase 2 Investigator-Sponsored Trial of Aldafermin for the Treatment of Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) and Bile Acid Malabsorption (BAM) at Digestive Disease Week 2023
Aldafermin demonstrated statistically significant reductions in serum 7αC4 (a marker of bile acid synthesis) and fecal bile acids versus placebo in patients with idiopathic BAM with IBS-DAround 25-50% of patients with diarrhea-predominant IBS (or IBS-D) have evidence of BAMFindings complete an extensive clinical data package that NGM Bio will leverage to seek a development partner for aldafermin; NGM Bio’s internal development efforts will continue to focus on its portfolio of four clinical-stag
Simply Wall St.Revenues Not Telling The Story For NGM Biopharmaceuticals, Inc. (NASDAQ:NGM)
You may think that with a price-to-sales (or "P/S") ratio of 5.8x NGM Biopharmaceuticals, Inc. ( NASDAQ:NGM ) is a...
ZacksNGM Biopharmaceuticals (NGM) Reports Q1 Loss, Misses Revenue Estimates
NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of -11.54% and 67.55%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
NGM Bio Reports First Quarter 2023 Financial Results and Provides Business Highlights, Including Topline ALPINE 4 Data
Phase 2b ALPINE 4 trial met its primary endpoint, demonstrating a statistically significant improvement in Enhanced Liver Fibrosis (ELF) score at 48 weeks versus baseline in patients with compensated cirrhosis (F4) due to NASH treated with 3 mg of aldafermin, an engineered FGF19 analog product candidate, compared to patients treated with placeboInitiated the first two Phase 2b expansion cohorts in the Phase 1/2 trial evaluating NGM707, an ILT2/ILT4 antagonist antibody product candidate, in combi
ZacksAnalysts Estimate ADC Therapeutics SA (ADCT) to Report a Decline in Earnings: What to Look Out for
ADC Therapeutics SA (ADCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksNGM Biopharmaceuticals (NGM) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
NGM Biopharmaceuticals (NGM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) insider upped their holding by 68% earlier this year
Looking at NGM Biopharmaceuticals, Inc.'s ( NASDAQ:NGM ) insider transactions over the last year, we can see that...
BenzingaClinical Setbacks Prompt NGM Bio Lay Off One Third Of Its Staff, Founder Leaves
NGM Biopharmaceuticals Inc (NASDAQ: NGM) announced will be reducing its workforce by 75 staffers, or a third of the workforce, to extend its cash runway into 2025. In its Q4 earnings, the company hinted at financial issues, narrowing its focus on oncology and intending to partner out some other programs in a cash-saving move. The company estimates it will incur approximately $5.0 million in restructuring charges in connection with the restructuring, with the majority in the second quarter of 202
- GlobeNewswire
NGM Bio to Participate in the Cowen 43rd Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will participate in the Cowen 43rd Annual Health Care Conference as part of the Novel Oncology Targets Panel and will provide a business update focusing on NGM Bio’s wholly-owned oncology portfolio on Tues
ZacksNGM Biopharmaceuticals (NGM) Reports Q4 Loss, Tops Revenue Estimates
NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 13.46% and 166.31%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial Results
--Presented preliminary findings from the Phase 1a monotherapy dose escalation portion of the ongoing Phase 1/2 trial of NGM707 in patients with advanced or metastatic solid tumors at the ESMO I-O Annual Congress-- --Initiated a Phase 1b cohort of the ongoing Phase 1/1b trial evaluating NGM438 in combination with KEYTRUDA® (pembrolizumab) for the treatment of patients with advanced or metastatic solid tumors-- SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals,
- Simply Wall St.
NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) is definitely on the radar of institutional investors who own 31% of the company
To get a sense of who is truly in control of NGM Biopharmaceuticals, Inc. ( NASDAQ:NGM ), it is important to understand...
- GlobeNewswire
NGM Bio to Participate in the B. Riley Securities 3rd Annual Oncology Conference
SOUTH SAN FRANCISCO, Calif., Jan. 12, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, and Siobhan Nolan Mangini, President and Chief Financial Officer, will participate in the B. Riley Securities 3rd Annual Oncology Conference and will provide a business update focusing on NGM Bio’s wholly-o
- GlobeNewswire
NGM Bio Outlines Corporate Strategy and Provides Guidance on Key Priorities
NGM Bio’s three-pronged corporate strategy includes the following components: Focus internal clinical development efforts on solid tumor oncology portfolioGenerate next-generation biologics through prolific in-house discovery engineSeek partners for other NGM-discovered programs including aldafermin, NGM621 and NGM936 2023 key priority to advance signal-seeking trials of myeloid checkpoint inhibitor immuno-oncology programs NGM707, NGM831 and NGM438 SOUTH SAN FRANCISCO, Calif., Jan. 09, 2023 (GL
- Simply Wall St.
We Think NGM Biopharmaceuticals (NASDAQ:NGM) Needs To Drive Business Growth Carefully
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
BenzingaAfter Disappointing Phase 2 Data, Merck Drops Eye Disease Related Pact With NGM Biopharm
Merck & Co Inc (NYSE: MRK) has notified NGM Biopharmaceuticals Inc (NASDAQ: NGM) that it will not exercise its option to license NGM621 and its related compounds. Merck will also not exercise the related ophthalmology bundle option. NGM estimated in its latest quarterly report that it could also have received $20.7 million in reimbursable expenses if Merck went ahead with NGM621. In June 2021, NGM Biopharma and Merck extended their ongoing collaboration through March 2024 with a narrower scope.
- GlobeNewswire
NGM Bio Gives Presentation Featuring Preclinical Characterization of NGM936 at 2022 ASH Annual Meeting
--NGM936, a ILT3 x CD3 bispecific T cell engager product candidate, potently induced T cell dependent cytotoxicity (TDCC) against ILT3+ AML cells while inducing minimal cytokine release in preclinical in vivo and in vitro studies-- --Immunoglobulin-like transcript 3 (ILT3) is a highly specific marker of acute myeloid leukemia (AML) with monocytic differentiation and is not expressed on non-monocytic blood cells or hematopoietic progenitor cells, making ILT3 a potentially promising target for mon
- GlobeNewswire
NGM Bio Presents Preliminary Data from Phase 1 Monotherapy Dose Escalation Trial of NGM707 in Patients with Advanced or Metastatic Solid Tumors at 2022 ESMO-IO Annual Meeting
NGM707 was generally well tolerated to the highest dose evaluated (1800 mg) in the monotherapy escalation; maximum tolerated dose was not reachedLinear pharmacokinetics (PK) was observed at doses ≥200 mg, and analysis of peripheral immune cells demonstrated dose-dependent receptor occupancy (RO), with doses ≥200 mg maintaining full ILT2 and ILT4 RO for the entire dosing interval to datePotential proof-of-mechanism (myeloid reprogramming) was observed in peripheral blood and tumor biopsiesEarly s
ZacksHow Much Upside is Left in NGM Biopharmaceuticals (NGM)? Wall Street Analysts Think 462%
The mean of analysts' price targets for NGM Biopharmaceuticals (NGM) points to a 461.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- Simply Wall St.
NGM Biopharmaceuticals Third Quarter 2022 Earnings: Beats Expectations
NGM Biopharmaceuticals ( NASDAQ:NGM ) Third Quarter 2022 Results Key Financial Results Revenue: US$7.91m (down 57% from...
- GlobeNewswire
NGM Bio Announces Poster Presentation Featuring Initial Findings from Ph1a Trial of NGM707 in Patients with Advanced Solid Tumors at Upcoming 2022 ESMO-IO Annual Meeting
Poster presentation to showcase initial data from the Phase 1a monotherapy dose escalation arm of the ongoing Phase 1/2 trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, in patients with advanced solid tumorsILT2 and ILT4, both upregulated in certain tumor types, are believed to serve as myeloid checkpoints, helping tumors evade immune detection. Furthermore, ILT2 may suppress the activity of certain lymphoid cell populations on which the receptor is expressedNGM707 is des
- GlobeNewswire
NGM Bio Announces Poster Presentation Featuring Preclinical Characterization of NGM936 at Upcoming 2022 ASH Annual Meeting
--Poster presentation to showcase NGM Bio’s in vitro and in vivo research supporting development of NGM936, a ILT3 x CD3 bispecific T cell engager product candidate engineered to direct T cell-mediated killing of ILT3-positive cancer cells-- --Oral presentation from the lab of Dr. Fabiana Perna at the Indiana University School of Medicine to showcase research done in collaboration with NGM Bio demonstrating the rationale for the study of NGM936 for the treatment of patients with multiple myeloma
ZacksNGM Biopharmaceuticals (NGM) Reports Q3 Loss, Tops Revenue Estimates
NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 3.28% and 12.66%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
NGM Bio Provides Business Highlights and Reports Third Quarter 2022 Financial Results
--Announced that the CATALINA Phase 2 trial of NGM621 in patients with geographic atrophy secondary to age-related macular degeneration did not meet primary endpoint of statistically significant rate of change in GA lesion area using slope analysis over 52 weeks for NGM621 versus sham-- --Presented updated preliminary findings from Phase 1a and Phase 1b cohorts evaluating NGM120 for the treatment of cancer at the ESMO Annual Congress and at the AACR Special Conference: Pancreatic Cancer-- --Upda